mondoBIOTECH Holding AG

On 25 January 2013 mondoBIOTECH Holding AG and Pierrel SpA announced that they had entered into a binding agreement for the combination of the Contract Research Organization (CRO) of Pierrel SpA with mondoBIOTECH.

Thereby, Pierrel SpA, a global pharmaceutical provider listed on the Italian stock exchange, will contribute 100% of the share capital of PIerrel Research International AG, the holding company of the CRO, by way of a contribution in kind through a dedicated capital increase of mondoBIOTECH, a Swiss drug discovery company focused on repurposing drugs in rare and neglected diseases which is listed on the Swiss stock exchange. The business combination is subject to a number of closing conditions.

A team of Froriep Renggli, lead by Partner Marco A. Rizzi and Dr. Mark Montanari, advises mondoBIOTECH Holding AG on all Swiss law aspects of the business combination.


zurück

Dazughöriger Professional

Dazughörige Practice Area